Media OutReach

Sun Life unveils suite of enhanced savings insurance plans

Published

5 months ago

03/07/2025

SunJoy Global Insurance Plan II, SunGift Global Insurance Plan II and Stellar Multi-Currency Insurance Plan II offer market-leading flexible Death Benefit Settlement Solution, multiple Contingent Policy Owner Arrangement and Interim Policy Owner Arrangement

HONG KONG SAR – Media OutReach Newswire – 3 July 2025 – Sun Life today announced the launch of an upgraded suite of savings insurance products. The upgraded products – SunJoy Global Insurance Plan II, SunGift Global Insurance Plan II, and Stellar Multi-Currency Insurance Plan II – are among Sun Life’s most popular offerings. Key enhancements include the introduction of a market-leading¹ mix of multiple Death Benefit Settlement Options, multiple Contingent Policy Owner² and Interim Policy Owner Arrangement². These upgrades are designed to help Clients capture wealth growth while seamlessly planning their wealth legacy.

Christine Yeung, General Manager, Life and Health of Sun Life Hong Kong Limited, said: “At Sun Life, we’re committed to putting our Clients at the centre of everything we do. We understand their evolving needs in wealth accumulation and legacy planning for both the present and the future. The innovative and flexible design of the SunJoy Global and SunGift Global series, along with the Stellar Multi-Currency Insurance Plan, plays a pivotal role in helping Clients shape their wealth legacy and meet increasingly diverse needs. These three upgraded savings insurance plans are equipped with brand-new wealth legacy features, empowering Clients to achieve their financial goals while offering unparalleled flexibility in passing on their wealth to future generations. Moving forward, we will continue to drive product innovation, offering pioneering protection and wealth planning solutions to help the public achieve lifetime financial security.”

The three upgraded savings plans are participating insurance plans. The two major enhancements include:

Market-leading flexible Death Benefit Settlement Option

Policy owners can mix and match multiple death benefit payout patterns with a Flexible Option, moving beyond package-based death benefit payment options.
Policy owners can design their own payout patterns for each beneficiary or choose a designated lump-sum payout upon designated life events of the beneficiary – such as graduating from university, getting married or having a child.
If the Designated Insured passes away, the Continuation Option^3,4 allows the Original Policy to immediately terminate and a New Policy to be formed, with a beneficiary becoming both the New Insured and the new policy owner⁵ (if applicable).

Market-rare multiple Contingent Policy Owner Arrangement and Interim Policy Owner Arrangement

Policy owners can designate up to three Contingent Policy Owners and designate up to three Interim Policy Owners for one of the Contingent Policy Owners⁶in sequence, ensuring the policy’s value and wealth is seamlessly passing on to future generations.
Interim Policy Owners will hold the policy on behalf of the Contingent Policy Owner until he/she attains the designated age or until the specified date is reached. They will have Restricted Administrative Rights to manage the policy, ensuring the wealth is transferred according to the policy owner’s plan.

The product upgrades enable Clients to tailor their wealth management and legacy plans according to their needs. The plans offer a variety of protections targeting different life stages, helping Clients cope with unexpected challenges, including:

Upgraded Product Features

Early Value Lock-in Option⁷: Starting from the 5^th policy anniversary, the policy owner can apply to transfer 10%-50% of the policy’s value to the Value Lock-in Account each policy year.

Whole life protection: The benefit term is extended to the whole life of the current insured (for single life) or the younger insured (for joint life).

Enhanced Guaranteed Death Benefit: 105%*/105%-120%** of total premium paid.

[*Only applicable to SunJoy Global Insurance Plan II and SunGift Global Insurance Plan II]

[**Only applicable to Stellar Multi-Currency Insurance Plan II]

Extended Incapacity Benefit coverage⁸: In addition to being diagnosed as mentally incapacitated, policy owners diagnosed with coma⁹, major head trauma¹⁰ or paralysis¹¹ can have a family member appointed as the Incapacity Benefit Recipient to file a claim.

Extended Waiver of Premium Benefit:

If the insured, who is also the policy owner, is diagnosed as suffering from Total Permanent Disability due to Injury or Sickness before age 70, Client can enjoy Waiver of Premium Benefit¹².

If the policy owner, who is not the insured, passes away or is diagnosed as suffering from Total Permanent Disability before age 70 due to Injury or Sickness, Client can enjoy Payor Benefit¹².

Academic Achievement Awards: An award is paid based on the insured’s academic achievement in the Hong Kong Diploma of Secondary Education Examination, TOEFL, IELTS, International Baccalaureate Diploma Program, Mainland Gaokao, SAT, or upon receiving an unconditional offer of admission to a full-time undergraduate program of the world’s top 10 universities.

[Only applicable to Stellar Multi-Currency Insurance Plan II]

Flexible choice of withdrawal currency: SunWallet supports currency exchange in up to 17 currencies, enabling easier 24/7 policy management

From now until July 31, 2025, Clients successfully apply upgraded series of savings insurance products can enjoy the following offers:

SunJoy Global Insurance Plan II/SunGift Global Insurance Plan II (5-pay) – Up to 74% of the annualized first year premium^#;
SunJoy Global Insurance Plan II/SunGift Global Insurance Plan II (2-pay) – Up to 10% of the annualized first year premium^#;
Stellar Multi-Currency Insurance Plan II – Up to 93% of the annualized first year premium^.

Remarks

¹“Market-leading” refers to the services provided by Sun Life, the data of savings plans of new policies offered by composite and long-term insurers on the Register of Authorised Insurers of the Insurance Authority, and market conditions as of July 1, 2025.

²This is an administrative arrangement and is not part of the product features. Please see the relevant leaflet and prescribed form for more details on the policy owner rights and the restrictions applicable to the designation of Contingent Policy Owner and the designation of Interim Policy Owner for the Contingent Policy Owner.

³If this option is selected, the beneficiary must be a living individual.

⁴Requests are subject to our approval. The New Policy will take effect from the Continuation Option Effective Date.

a. The Policy Date and the policies years of the New Policy will be the same as the Original Policy.

b. The Notional Amount, total premiums due and paid, outstanding amount of any loans and interest, and the policy values of the Original Policy, including Guaranteed Cash Value, accumulated Reversionary Bonus (if any), Terminal Bonus (if any) and the amount in the Value Lock-in Account (if any) will be allocated to the New Policy according to the designated percentage to the corresponding beneficiary according to the policy owner’s instructions.

c. There is no cooling-off period for the New Policy, and

d. For the purpose of counting the applicable period under the Incontestability provision, the relevant period will commence from the Continuation Option Effective Date for the New Insured.

⁵The beneficiary will become both the New Insured and the new policy owner if (i) the designated insured who is also the policy owner has died; or (ii) the designated insured is not the policy owner, and the policy owner and the designated insured die at the same time; or (iii) the policy owner dies within 14 days after the death of the designated insured.

⁶He/she must be the Designated Insured.

⁷The Notional Amount after the Value Lock-in Option is exercised cannot be less than the minimum amount requirement.

⁸The irrevocable beneficiary(ies) (if any) and the assignee (if any) must agree in writing to the requested designation of (a) the Incapacity Benefit Recipient; and (b) the Incapacity Benefit Percentage. Any existing Incapacity Benefit Recipient will be automatically revoked when (a) the policy owner designate a new Incapacity Benefit Recipient and the policy owner’s request is approved by us; (b) the policy owner is changed; (c) Sun Life HK has been notified that there is a guardian or committee appointed under the Mental Health Ordinance (Cap. 136 Laws of Hong Kong SAR) (or if there is a guardian or committee appointed under similar laws in another jurisdiction); or (d) Sun Life HK has been notified that the policy owner has an enduring power of attorney covering the policy. In the event that there is a dispute between the Incapacity Benefit Recipient and any other person, including but not limited to the insured’s guardian, committee, attorney, beneficiary(ies), assignee or in our reasonable belief that there is such a dispute, Sun Life HK reserves the right to withhold the payment of the Incapacity Benefit until such dispute is resolved.

⁹Coma means a state of unconsciousness with no reaction to external stimuli or internal needs persisting continuously with the use of life support systems for a period of at least 1 week and resulting in a neurological deficit, which in our medical officer’s opinion is of a permanent nature.

¹⁰Major Head Trauma means major trauma to the head with disturbance of the brain function confirmed by definite diagnosis by a consultant neurologist acceptable to us. The disturbance must result in a permanent bedridden situation or the inability to perform without assistance 3 or more Activities of Daily Living.

¹¹Paralysis means permanent loss of muscular power of both arms or both legs due to the disorder of the brain and nervous system and confirmed by a Specialist in the relevant medical field.

¹²This benefit is subject to maximum amount, terms and conditions, pre-existing conditions and exclusions listed in the policy document.

^#It includes basic rebate and green offer (guaranteed prepayment interest rate applies and only applicable to policies in United States Dollars). Terms and conditions apply. Please refer to the promotional leaflet for details.

^ It includes basic rebate, Enhanced Rebate and green offer (guaranteed prepayment interest rate applies and only applicable to policies in United States Dollars). Terms and conditions apply. Please refer to the promotional leaflet for details.

Hashtag: #SunLife永明 #永明金融 #SunLife #儲蓄保險 #分紅保險 #財富傳承 #萬年青 #星河尊享 #星河傳承 #永越 #身故保障 #後補保單主權人 #保單暫托人 #savingsinsurance #participatinginsurance #wealthlegacy #SunJoy #SunGift #Stellar #deathbenefit #policyowner #contingentpolicyowner #interimpolicyowner

The issuer is solely responsible for the content of this announcement.

About Sun Life

Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of March 31, 2025, Sun Life had total assets under management of $1.55 trillion. For more information, please visit www.sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF. Sun Life Financial Inc. is the holding company of Sun Life Assurance Company of Canada. Sun Life Hong Kong Limited is a wholly-owned subsidiary of Sun Life Assurance Company of Canada.

Media OutReach

MIMO: The AI-Native Storage Species Enables Desktop Scale AI Clusters With NVIDIA DGX Spark

Published

11 hours ago

12/12/2025

Media Outreach

Engineered for the AI era, MIMO delivers breakthrough metrics: 400 GB/s bandwidth, 54 million IOPS, and 40–90 μs latency—all within a form factor comparable to a large suitcase.
MIMO serves as both a high-performance data hub for large-scale GPU clusters and a flexible edge deployment platform, extending seamlessly to desktop environments where it orchestrates workflows with various DGX Spark units based on NVIDIA’s GB10 Grace Blackwell superchip.
This architecture enables independent AI clusters supporting up to 16 computing nodes within constrained environments, managing the complete workflow from large-scale pre-training and fine-tuning to production inference—effectively democratizing enterprise-grade AI capabilities for labs, edge sites, and distributed teams.

SINGAPORE –

Professor Zhang Sheng from Tsinghua University Shenzhen International Graduate School expressed a more pragmatic view: “With this solution, we finally no longer have to rely on the university’s data center. Our current annual budget alone is enough to deploy an AI cluster within our lab that better fits our needs—this will significantly boost our research efficiency both technically and operationally. It’s truly fantastic news.”

Asia Debut Marks Industry Inflection Point

Earlier at the 8th China International Import Expo (CIIE), the solution’s core—the world’s first AI-native storage system MIMO—made its strategic Asian debut. Engineered for the AI era, MIMO delivers breakthrough metrics: 400 GB/s bandwidth, 54 million IOPS, and 40–90 μs latency—all within a form factor comparable to a large suitcase.

The platform’s defining Fast-Light-Edge proposition, delivered through its breakthrough architecture, cut through the exhibition noise, generating immediate and widespread attention. MIMO earned exclusive features in top-tier media including Hong Kong Ta Kung Pao and China Securities Journal, while its product demonstration videos gained rapid traction across leading digital channels.

Addressing Foundational Challenges: Technical Dialogues That Matter

During the exhibitions, technical leaders from the United States, Spain, Singapore, Colombia, the UAE (Dubai), India, Pakistan, and Hong Kong SAR engaged in substantive dialogues with Ridger’s Asia team, raising questions that revealed systemic industry gaps:

Architectural Transformation & Strategic Positioning
“Can MIMO fundamentally replace legacy storage architectures—traditional NAS, unified, distributed, and parallel file systems—to deliver accelerated parallel training and high-concurrency inference?”
“With such exceptional performance, would deploying MIMO for traditional enterprise applications represent strategic overinvestment or forward-looking infrastructure?”

Mobile Deployment & Borderless Operations
“MIMO’s suitcase-sized footprint suggests unprecedented mobility. Can it truly accompany research teams globally like standard equipment? How does it maintain operational continuity across jurisdictions? What’s the customs protocol for such ‘technical luggage’?”

Seamless Integration & Global Accessibility
“In scenarios with unnetworked AI servers, can MIMO rapidly establish dedicated training environments with true plug-and-play functionality?”
“Does MIMO integrate transparently with existing AI infrastructure and software stacks without requiring modifications?”
“Beyond Asia-Pacific, what’s the procurement pathway for MIMO? Which currencies and payment methods are accommodated?”

Architectural Breakthrough: Redefining What’s Possible

Addressing these operational realities, Ridger demonstrated MIMO’s system-level value—transcending its role as a storage device to become an architectural cornerstone. MIMO serves as both a high-performance data hub for large-scale GPU clusters and a flexible edge deployment platform, extending seamlessly to desktop environments where it orchestrates workflows with various DGX Spark units based on NVIDIA’s GB10 Grace Blackwell superchip.

Notably, eight global OEM partners—including Dell, HPE, Lenovo, xFusion, H3C, MSI, GIGABYTE, and Acer—have concurrently launched Spark versions based on NVIDIA’s GB10 Grace Blackwell superchip, creating a robust compatibility foundation for MIMO’s ecosystem integration.

This architecture enables independent AI clusters supporting up to 16 computing nodes within constrained environments, managing the complete workflow from large-scale pre-training and fine-tuning to production inference—effectively democratizing enterprise-grade AI capabilities for labs, edge sites, and distributed teams.

As Zhu Ting, an industry observer from Beijing, noted: “This represents the ‘IBM PC moment’ for AI infrastructure—transforming specialized capability into accessible utility.”

Market Validation Through Early Adoption

Market response has been decisive. Following the exhibitions, pioneering organizations across pathological image foundation model development, legal-tech innovation, industrial visual inspection, and naked-eye 3D content production have joined Ridger’s Early Access program, validating the architecture’s transformative potential in real-world operational contexts.

Global Rollout: Accelerating Accessibility

Responding to accelerating global demand, Ridger confirmed the imminent launch of the complete MIMO portfolio and optimized solution bundles for specific DGX Spark configurations through the Ridger Official Global Store. Designed as a frictionless procurement channel, the platform will support diverse payment options including multiple fiat currencies and cryptocurrencies—streamlining access to advanced AI infrastructure.

Organizations seeking deeper understanding of MIMO and its integrated lightweight AI solution with DGX Spark are invited to connect with Ridger team or its strategic partner, NVIDIA Elite Solution Partner SinoInfo.
Hashtag: #Technology #ESG #AI #GPU #Enterprise #Finance #Storage #Flash #Compute #DGX-Spark #NVIDIA #AI-Lab #GDS #NAS #AI-Native

https://ridger.tech/
https://www.linkedin.com/company/ridger/
https://www.youtube.com/@ridgertech

The issuer is solely responsible for the content of this announcement.

Ridger

Ridger is a global technology pioneer building next-generation computing & storage infrastructure for the AI era. Born in the East and operating worldwide, Ridger challenges conventional paths to create new technological paradigms.

The team unites seasoned experts from global storage leaders with visionary AI architects, all driven by a shared mission to democratize cutting-edge technology, rejects incremental improvements and hollow prestige, focusing exclusively on foundational breakthroughs that deliver tangible value and sustainable impact.

From architecture to implementation and from service to empowerment, Ridger provides end-to-end solutions that help clients worldwide ascend to their highest summits.

Media OutReach

Johnson & Johnson and Asia Pacific Patient Advocacy Group Leaders Unite to Strengthen Shared Decision-Making in Lung Cancer Care

Published

12 hours ago

12/12/2025

Media Outreach

Patient survey finds that those engaged in shared decision-making were 11 times more likely to report higher satisfaction with their treatments, with 90% of lung cancer patients in Japan wanting to play an active role in their treatment decisions[1]

J&J deepens its commitment to patient empowerment in Asia Pacific by launching J&J withMe, a new patient portal offering tailored patient resources, and co-driving market-specific initiatives with patient advocacy groups

SINGAPORE – Media OutReach Newswire – 11 December 2025 – Johnson & Johnson announced the next phase of The 3rd Opinion campaign across Asia Pacific, focused on championing shared decision-making between lung cancer patients and healthcare professionals through events and stakeholder engagements at ESMO Asia 2025 in Singapore.

At a Patient Reception on 6^th December 2025, 20 leaders from 17 patient advocacy groups from across Asia Pacific, Europe and the United States shared their support for the need to strengthen shared decision-making. On December 7, 2025, the ESMO Asia 2025 Symposium, ‘Advancing EGFRm NSCLC Treatment Through Shared Decision-Making’ highlighted the role of healthcare professionals not only in making sense of the data but also in helping patients and their families navigate complex decision-making.

“High prevalence in Asia of certain NSCLC mutations makes the choice of first-line therapy absolutely critical. Treatment decisions must balance clinical objectives with patient values — weighing disease biology, survival prospects, durable disease control and the tradeoffs of side effects. That’s why shared decision-making is essential: clinicians should present all appropriate treatment options, so the final choice is collaborative and aligned with each patient’s goals,” said Professor Zhu Zhengfei, Director of the Radiation Oncology Department, Fudan University Shanghai Cancer Center.

“When lung cancer patients are empowered to speak up and understand their options, they are more likely to continue the treatment and their dignity is preserved. Initiatives like ‘The 3rd Opinion’ are vital for fostering truly patient-centered partnerships between people living with cancer and their healthcare teams,” noted Ms. Liu Yiting, Marketing & Branding Director, China MeetHealth Mi-Jian Patient Community.

“The shared commitment validates what many people living with lung cancer have long expressed: shared decision making is essential. From our experience supporting patients, meaningful conversations with clinicians help acknowledge patients’ experiences, address their concerns, and preserving their hopes,” added Mr. Jung-Il Cho, Chairman of Korea Lung Cancer Patients Association.

Our commitment comes off the back of a recent patient survey revealing that 90% of Japanese lung cancer patients want to play an active role in their treatment decisions. The survey also found that shared decision-making, where physicians and patients jointly compare treatment options and decide together, is the strongest driver of treatment satisfaction.¹

To bridge the gap between patients’ desire to engage in shared decision making and their lack of practical support, J&J has launched “J&J withMe”, an online hub that equips lung cancer patients and caregivers with tailored toolkits and conversation guides to prepare for consultations and make informed, personalized treatment decisions.

Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific said, “The 3rd Opinion truly puts patients at the center of care. As part of our deep commitment to address patients’ unmet needs, we will continue partnering with patient advocacy groups and healthcare professionals to help patients to find their voice and the moment when medical advice meets what truly matters to patients.”

In recognition of diverse cultural and clinical norms across Asia Pacific, J&J has also rolled out tailored market activations in collaboration with local patient advocacy groups:

Provision of patient resources such as the “Lung Cancer Book of Answers” in China, ‘Value of Time’ video for patients in Japan, and educational assets in India and Australia/New Zealand;
Digital and social media engagement featuring patients and creators discussing the importance of shared decision-making across Singapore, Malaysia, Philippines, Thailand, and Vietnam;
Event engagement via the establishment of a patient advisory board in India;
Corporate Social Responsibility program with a lung cancer patient group in Korea, bringing employees and patients together to better understand the disease burden of patients and strengthen emotional support for the patient community.

###

About the 3^rd Opinion

“The 3rd Opinion”, the patient’s own opinion, is a new term that sparks a social movement in the lung cancer treatment journey – designed to elevate the patient voice and empower individuals to take an active role in shaping their treatment plan. By prioritizing shared decision-making between patients and healthcare professionals, this collaborative approach ensures that treatment choices are aligned to each patient’s goals, preferences and circumstances. This results in more informed decisions, greater patient satisfaction, and the best possible outcomes.

About Non-Small Cell Lung Cancer

Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[1]^, [2] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[3] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[4] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[5]^{, [6],[7],[8],[9],[10]}EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[11] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent.[12]^,[13] EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[14] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[15]By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90% and 97% respectively[16].

[1] Johnson & Johnson lung cancer patient quantitative survey conducted in Japan, 2025

[2] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[3] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[4] Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.

[5] Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[6] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[7] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[8] Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol. 37:97-104.

[9] Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[10] Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.

[11] Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.

[12] American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed March 2025.

[13] Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.

[14] Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65

[15] Arcila, M. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013 Feb; 12(2):220-9.

[16] Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[17] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, 2024.

Hashtag: #Johnson&Johnson

The issuer is solely responsible for the content of this announcement.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.

Johnson & Johnson Innovative Medicine Asia Pacific, a division of Johnson & Johnson International (Singapore) Pte. Ltd is a Johnson & Johnson company.

Media OutReach

Skychakra Global Capital Strategy Upgrade: Advancing Cross-Border Listings and RWA Ecosystem

Published

23 hours ago

11/12/2025

Media Outreach

HONG KONG SAR – Media OutReach Newswire – 11 December 2025 – Skychakra Group recently held a grand inauguration ceremony at the Hong Kong International Center, announcing the official acceleration of its globalization strategy. With a mission to “enhance individual energy, empower enterprise growth, and promote asset capitalization,” Skychakra simultaneously launched three major international initiatives: a cross-border listing incubation system, an RWA (Real World Assets) technology ecosystem, and the international upgrade of mind-body energy science, building a new economic ecosystem that spans technology, industry, and capital.

As a global hub for innovation and capital, Hong Kong serves as a significant gateway for the activation of Skychakra’s global strategy. This inauguration not only symbolizes the completion of the facility but also marks the comprehensive rollout of Skychakra’s international layout.

Official Launch of Cross-Border Listing Incubation Center

During the inauguration, Skychakra announced the establishment of a cross-border listing incubation center, led by a professional team qualified with SEC, PCAOB, and FINRA credentials, boasting over a hundred projects in cross-border listings. The service scope includes U.S. stocks, Hong Kong stocks, and SPACs. Unlike traditional investment banks and financial advisors, Skychakra offers a “full-link” service for enterprise capitalization, encompassing red-chip structure setup, financial and audit compliance, SEC and Hong Kong Stock Exchange filing guidance, dual-path IPO/SPAC design, market value management, enterprise internationalization guidance, and digital upgrades.

Originally planning to sign contracts for four companies at the conference, Skychakra exceeded expectations by signing 12, demonstrating its strong appeal and industry influence in cross-border listings and capital operations.

RWA Technology Ecosystem: Making Enterprise Assets Visible to the Financial System

Real World Assets (RWA) are becoming the core of global financial transformation. From BlackRock’s launch of tokenized funds to Hong Kong and Singapore incorporating RWA into financial infrastructure, RWAs are transitioning from concept to large-scale implementation. Skychakra emphasizes that small and medium-sized enterprises face common challenges such as lack of recognition for their assets within the financial system, difficulties in cross-border financing, and a lack of transparency in asset value.

The Skychakra RWA ecosystem will provide enterprises with: tokenizable asset identification, asset structuring and entitlement, on-chain mapping and minting, cross-border compliance design, global issuance and liquidity channels, and on-chain risk control and transparent tracking. The core value of RWA lies in reducing friction for enterprises in connecting to global capital, enhancing asset liquidity and valuation potential.

A Holistic Growth Model: “From People to Enterprises, From Enterprises to Capital”

Skychakra’s differentiated advantage stems from its foundational logic of “starting with people.” The Skychakra energy courses utilize scientific equipment to measure energy fields, emotional frequencies, and meridian states, assisting individuals in enhancing stability, insight, and decision-making abilities.

Based on this foundation, Skychakra constructs three major systems:

1. Enterprise Growth System: Enhancing organizational capabilities, introducing international business, and providing capital operation guidance.

2. Capitalization System: Building global financing capabilities through listings and RWA structures.

3. Asset Digitalization System: Making enterprise value quantifiable, verifiable, and tradable.

These three systems dynamically interact in a spiral structure, forming Skychakra’s unique full-link growth ecosystem.

Conclusion: Global Layout for Greater International Influence

The inauguration of Skychakra’s Hong Kong International Center signifies the official implementation of the group’s globalization strategy. Looking forward, the focus will be on Hong Kong as the core, with Asia as the main axis, while establishing deep collaborations with the North American and Middle Eastern markets. Through this global layout, Skychakra is creating a new organizational model that transcends regions, industries, and capital, enabling enterprises to achieve value flow in the global market and allowing more Asian companies to gain a stronger voice on the international stage.

Hashtag: #Skychakra

The issuer is solely responsible for the content of this announcement.